Italy
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.7 (0.40 - 1) | 2016 | Modelled | ECDC |
0.5 (0.30 - 1) | 2007 | Survey/reported | Cozzolongo R et al, 2009 |
0.8 (0.40 - 1.30) | 2003 | Survey/reported | Pendino GM, 2005 |
0.7 (0 - 3.90) | 2001 | Survey/reported | Floreani A, 2006 |
1.67 (1.26 - 2.17) | 2015 | Modelled | WHO |
0.6 (0.30 - 0.70) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
2.52 (2.49 - 2.54) | 2013 | Modelled | Schweitzer et al, 2015 |
0.71 (0.62 - 0.80) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
0.76 (0.66 - 0.85) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.76 (0.66 - 0.86) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.79 (0.69 - 0.88) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.82 (0.72 - 0.91) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.83 (0.73 - 0.92) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.85 (0.75 - 0.94) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.87 (0.77 - 0.97) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.89 (0.79 - 0.99) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.91 (0.81 - 1.01) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.92 (0.82 - 1.03) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.95 (0.85 - 1.05) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.98 (0.88 - 1.08) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
1 (0.90 - 1.11) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.02 (0.91 - 1.13) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.03 (0.92 - 1.14) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.05 (0.94 - 1.15) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.07 (0.96 - 1.17) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.08 (0.98 - 1.19) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.1 (0.99 - 1.21) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.11 (1 - 1.22) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.14 (1.03 - 1.25) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.18 (1.06 - 1.29) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.21 (1.09 - 1.32) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.22 (1.11 - 1.34) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.24 (1.12 - 1.36) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.26 (1.13 - 1.38) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.28 (1.15 - 1.41) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.31 (1.18 - 1.44) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.34 (1.20 - 1.48) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.76 (0.66 - 0.85) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
1 | 2020 | Modelled | CDA Foundation |
Showing out of
Show more
Children under-5 years
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.61 (0.39 - 0.93) | 2015 | Modelled | WHO |
0.03 (0.02 - 0.03) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
0.04 (0.03 - 0.05) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.05) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.05) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.06) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.06) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.06) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.06) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.06) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.06) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.06) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.06) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.06) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.06) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.06) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.06) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.04 (0.03 - 0.06) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.06) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.06) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.06 (0.04 - 0.08) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.06 (0.05 - 0.08) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.07 (0.06 - 0.09) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.09 (0.07 - 0.11) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.1 (0.08 - 0.13) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.12 (0.09 - 0.15) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.15 (0.11 - 0.19) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.18 (0.14 - 0.24) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.22 (0.17 - 0.29) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.27 (0.20 - 0.35) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.33 (0.28 - 0.39) | 2020 | Modelled | WHO |
Showing out of
Show more
Pregnant women
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.8 (0.70 - 1) | 2016 | Modelled | ECDC |
0.9 (0.70 - 1) | 2009 | Survey/reported | Spada E et al, 2014 |
0.8 (0.60 - 1) | 2012 | Survey/reported | Ruffini E et al, 2014 |
Showing out of
Show more
Prisoners
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
6.7 (5.20 - 8.40) | 2002 | Survey/reported | Babudieri S et al, 2005 |
Number of people living with chronic HBV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
332,000 (202,000 - 430,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
430,090 (375,354 - 483,967) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
439,721 (384,369 - 495,502) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
441,741 (385,899 - 497,174) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
443,503 (387,293 - 498,306) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
458,918 (401,987 - 513,137) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
475,434 (418,888 - 528,429) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
481,465 (424,356 - 534,668) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
492,970 (434,891 - 547,159) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
506,696 (447,869 - 560,975) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
518,933 (459,120 - 574,897) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
525,494 (466,440 - 583,723) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
531,282 (473,293 - 588,571) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
541,662 (484,181 - 598,770) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
553,539 (495,660 - 611,375) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
563,654 (504,798 - 623,636) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
568,198 (508,040 - 628,390) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
570,523 (511,719 - 629,477) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
576,132 (517,145 - 635,826) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
583,861 (524,542 - 643,464) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
591,359 (531,446 - 650,153) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
596,054 (536,025 - 655,866) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
603,806 (542,915 - 664,011) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
619,101 (558,596 - 679,650) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
637,413 (576,660 - 697,192) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
654,156 (591,933 - 715,070) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
664,623 (600,488 - 727,822) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
672,531 (607,644 - 736,655) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
684,165 (616,294 - 750,830) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
698,366 (628,952 - 767,565) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
713,941 (641,960 - 786,075) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
729,702 (653,248 - 806,083) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
DownloadValue (per 100,000) | Year | Type | Source |
---|---|---|---|
2.84 (2.52 - 3.19) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
5.03 (4.55 - 5.52) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.83 (4.37 - 5.31) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.57 (4.13 - 5.04) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.41 (3.99 - 4.87) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.18 (3.78 - 4.60) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.3 (3.88 - 4.74) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.13 (3.74 - 4.56) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.13 (3.74 - 4.55) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.14 (3.75 - 4.55) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.13 (3.73 - 4.55) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.04 (3.66 - 4.46) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.74 (3.39 - 4.12) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.9 (3.53 - 4.30) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.57 (3.21 - 3.93) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.34 (3 - 3.69) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.19 (2.87 - 3.55) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.07 (2.76 - 3.41) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.96 (2.66 - 3.29) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.88 (2.58 - 3.20) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.81 (2.53 - 3.13) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.77 (2.48 - 3.08) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.75 (2.48 - 3.07) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.75 (2.47 - 3.07) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.71 (2.42 - 3.03) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.67 (2.39 - 2.99) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.61 (2.33 - 2.92) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.7 (2.39 - 3.03) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.7 (2.41 - 3.02) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.77 (2.46 - 3.12) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.84 (2.52 - 3.19) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
3,509 | 2016 | Modelled | WHO |
2,854 (2,583 - 3,134) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,741 (2,481 - 3,012) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,595 (2,345 - 2,857) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,432 (2,196 - 2,679) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,500 (2,261 - 2,758) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,362 (2,136 - 2,600) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,333 (2,111 - 2,573) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,336 (2,117 - 2,569) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,330 (2,109 - 2,568) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,334 (2,111 - 2,572) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,290 (2,072 - 2,525) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,137 (1,934 - 2,355) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,219 (2,008 - 2,446) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,048 (1,845 - 2,257) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,933 (1,737 - 2,137) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,863 (1,673 - 2,069) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,755 (1,574 - 1,946) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,805 (1,619 - 2,004) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,689 (1,518 - 1,881) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,716 (1,540 - 1,906) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,668 (1,500 - 1,860) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,669 (1,499 - 1,858) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,670 (1,498 - 1,862) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,645 (1,474 - 1,841) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,587 (1,413 - 1,773) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,626 (1,452 - 1,818) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,643 (1,465 - 1,834) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,633 (1,451 - 1,836) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,676 (1,488 - 1,884) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,714 (1,517 - 1,927) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,714 (1,517 - 1,927) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
95 | 2019 | Survey/reported | WHO/UNICEF |
94 | 2020 | Survey/reported | WHO/UNICEF |
94 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Proportion of persons living with HBV diagnosed
Percent of PWID accessing OST
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
30 | 2017 | Survey/reported | EMCDDA, 2019 |
HBV National Action Plan
HBV elimination goal
HBV testing policy
None
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.1 (0.70 - 1.30) | 2015 | Modelled | Blach et al, 2017 |
1.87 (1.51 - 2.30) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.87 (1.51 - 2.28) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.85 (1.50 - 2.26) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.82 (1.48 - 2.22) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.79 (1.46 - 2.18) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.81 (1.48 - 2.21) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.88 (1.53 - 2.29) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.96 (1.60 - 2.39) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.03 (1.65 - 2.48) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.07 (1.69 - 2.52) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.07 (1.70 - 2.53) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.08 (1.70 - 2.52) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.08 (1.70 - 2.52) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.08 (1.71 - 2.52) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.09 (1.72 - 2.52) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.14 (1.75 - 2.58) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.23 (1.84 - 2.70) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.35 (1.93 - 2.82) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.44 (2 - 2.93) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.48 (2.03 - 2.98) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.49 (2.03 - 2.99) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.49 (2.03 - 2.99) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.48 (2.02 - 2.99) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.46 (2.01 - 2.98) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.44 (1.99 - 2.95) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.39 (1.96 - 2.90) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.32 (1.90 - 2.81) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.23 (1.83 - 2.70) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.12 (1.74 - 2.57) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
2 (1.64 - 2.43) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.78 (1.44 - 2.19) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
0.68 (0.54 - 0.82) | 2020 | Modelled | Kondili et al, 2022 |
Showing out of
Show more
Pregnant women
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.39 (0.38 - 0.40) | 2018 | Survey/reported | Piffer et al, 2020 |
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
56.61 | 2016 | Survey/reported | EMCDDA |
57.26 | 2015 | Survey/reported | EMCDDA |
54 | 2014 | Survey/reported | EMCDDA |
49.6 | 2013 | Survey/reported | EMCDDA |
67.52 | 2012 | Survey/reported | EMCDDA |
60.48 | 2010 | Survey/reported | EMCDDA |
58.52 | 2009 | Survey/reported | EMCDDA |
59.24 | 2008 | Survey/reported | EMCDDA |
60.21 | 2007 | Survey/reported | EMCDDA |
61.95 | 2006 | Survey/reported | EMCDDA |
61.4 | 2005 | Survey/reported | EMCDDA |
63.5 | 2004 | Survey/reported | EMCDDA |
64.9 | 2003 | Survey/reported | EMCDDA |
64.89 | 2002 | Survey/reported | EMCDDA |
66.32 | 2001 | Survey/reported | EMCDDA |
67.4 | 2000 | Survey/reported | EMCDDA |
67.14 | 1999 | Survey/reported | EMCDDA |
67.45 | 1998 | Survey/reported | EMCDDA |
67.1 | 1997 | Survey/reported | EMCDDA |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.65 (0.44 - 1.58) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
5.9 (5.20 - 6.60) | 2016 | Modelled | ECDC |
2.6 (2 - 3.40) | 2007 | Survey/reported | Cozzolongo R et al, 2009 |
6.5 (5.40 - 7.80) | 2003 | Survey/reported | Pendino GM, 2005 |
10.2 (8 - 12.70) | 2001 | Survey/reported | Floreani A, 2006 |
2 (1.60 - 7.30) | 2014 | Survey/reported | Gower et al, 2014 |
2.43 | 2019 | Modelled | Jin et al. 2017 |
Showing out of
Show more
Pregnant women
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.4 (0.30 - 0.50) | 2012 | Survey/reported | Ruffini E et al, 2014 |
Men who have sex with men (MSM) Living with HIV
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
4.4 (2.10 - 7.20) | 2019 | Modelled | Jin et al. 2017 |
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
57.9 (52.50 - 63.30) | 2014 | Modelled | Degenhardt L et al, 2017 |
60.5 (56.80 - 64) | 2010 | Survey/reported | EMCDDA |
64.33 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
Men who have sex with men (MSM)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
2.6 | 2019 | Modelled | Jin et al. 2017 |
Prisoners
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
38 (35 - 41.20) | 2002 | Survey/reported | Babudieri S et al, 2005 |
Number of people living with chronic HCV (RNA+/cAg)
National
DownloadValue | Year | Type | Source |
---|---|---|---|
680,000 (455,000 - 1,641,000) | 2015 | Modelled | Blach et al, 2017 |
1,093,900 (897,393 - 1,329,570) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,157,250 (946,954 - 1,402,000) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,214,640 (996,202 - 1,468,060) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,263,390 (1,036,430 - 1,528,880) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,300,570 (1,064,350 - 1,573,030) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,323,380 (1,081,360 - 1,600,160) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,335,800 (1,091,000 - 1,616,140) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,343,370 (1,096,910 - 1,623,860) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,347,130 (1,100,360 - 1,622,780) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,348,300 (1,101,750 - 1,622,010) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,348,100 (1,102,000 - 1,622,920) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,328,980 (1,087,700 - 1,599,910) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,283,040 (1,052,370 - 1,545,670) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,228,000 (1,008,830 - 1,482,300) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,182,630 (970,869 - 1,427,460) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,164,400 (956,405 - 1,407,180) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,168,340 (959,118 - 1,414,540) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,176,140 (961,936 - 1,427,070) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,184,860 (968,904 - 1,438,210) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,191,660 (973,113 - 1,448,220) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,193,460 (973,720 - 1,457,500) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,176,420 (959,232 - 1,433,930) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,138,150 (927,387 - 1,388,430) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,093,320 (890,300 - 1,330,310) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,057,350 (860,264 - 1,284,440) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,045,250 (850,828 - 1,269,380) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,061,770 (865,680 - 1,295,290) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,081,010 (878,737 - 1,319,930) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,087,730 (883,104 - 1,334,120) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,088,890 (883,078 - 1,335,280) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,074,970 (869,359 - 1,320,490) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue | Year | Type | Source |
---|---|---|---|
81,800 (54,700 - 197,000) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
DownloadValue (Deaths per 100,000) | Year | Type | Source |
---|---|---|---|
13.3 (11.80 - 14.70) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
15.38 (14.17 - 16.63) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
15.67 (14.42 - 16.93) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
15.77 (14.47 - 17.04) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
15.95 (14.68 - 17.23) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
16.08 (14.82 - 17.32) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
15.84 (14.61 - 17.13) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
15.69 (14.46 - 16.96) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
15.53 (14.31 - 16.77) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
15.41 (14.24 - 16.70) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
15.29 (14.14 - 16.52) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
14.97 (13.83 - 16.20) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
14.27 (13.07 - 15.46) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
14.63 (13.46 - 15.81) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
13.76 (12.56 - 14.92) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
13.16 (11.94 - 14.37) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
12.66 (11.43 - 13.85) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
12.84 (11.60 - 14.02) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
12.63 (11.38 - 13.80) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
12.74 (11.44 - 13.91) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
12.88 (11.54 - 14.05) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
12.85 (11.49 - 14.01) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
12.98 (11.60 - 14.16) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
13.04 (11.62 - 14.23) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
12.86 (11.46 - 14.05) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
12.74 (11.34 - 13.93) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
12.85 (11.39 - 14.06) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
12.4 (11.01 - 13.57) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
12.74 (11.32 - 14) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
13.07 (11.59 - 14.33) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
13.35 (11.77 - 14.68) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
10,470 | 2016 | Modelled | WHO |
8,050 (7,096 - 8,856) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,050 (7,096 - 8,856) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
7,905 (7,007 - 8,662) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,719 (6,858 - 8,483) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,523 (6,682 - 8,238) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,811 (6,923 - 8,542) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,748 (6,896 - 8,468) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,816 (6,969 - 8,542) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,919 (7,057 - 8,637) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,861 (7,027 - 8,576) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,772 (6,962 - 8,476) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,709 (6,897 - 8,410) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,596 (6,822 - 8,292) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,477 (6,734 - 8,167) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,436 (6,715 - 8,140) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,486 (6,767 - 8,179) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,614 (6,909 - 8,313) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
7,904 (7,211 - 8,568) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,149 (7,465 - 8,829) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,318 (7,651 - 8,992) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,485 (7,839 - 9,180) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,644 (7,994 - 9,338) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,703 (8,043 - 9,427) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,768 (8,078 - 9,466) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,857 (8,161 - 9,577) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,950 (8,257 - 9,679) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
9,097 (8,384 - 9,798) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
9,036 (8,315 - 9,759) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,945 (8,204 - 9,662) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,894 (8,187 - 9,612) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
8,734 (8,050 - 9,446) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of persons initiating HCV treatment
National
DownloadValue | Year | Type | Source |
---|---|---|---|
30,161 | 2015 | Survey/reported | Agenzia Italiana el Farmaco, 2023 |
34,066 | 2016 | Survey/reported | Agenzia Italiana el Farmaco, 2024 |
44,660 | 2017 | Survey/reported | Agenzia Italiana el Farmaco, 2025 |
56,499 | 2018 | Survey/reported | Agenzia Italiana el Farmaco, 2026 |
36,348 | 2019 | Survey/reported | Agenzia Italiana el Farmaco, 2027 |
15,664 | 2020 | Survey/reported | Agenzia Italiana el Farmaco, 2028 |
14,481 | 2021 | Survey/reported | Agenzia Italiana el Farmaco, 2029 |
Showing out of
Show more
Cumulative number of persons treated for HCV
National (2015-2021)
DownloadValue | Year | Type | Source |
---|---|---|---|
231,879 | 2021 | Survey/reported | Agenzia Italiana el Farmaco, 2022 |
Percent of PWID accessing OST
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
30 | 2017 | Survey/reported | EMCDDA, 2019 |
Proportion of persons living with HCV diagnosed
HBV National Action Plan
HBV elimination goal
HBV testing policy
None
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Overview
HBV elimination goal
HCV elimination goal
Hepatitis related deaths (national)
Modelled
HBV
1,714
2019
(1,517 - 1,927)
IHME, GBD 2019 (accessed 2020)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
8,050
2019
(7,096 - 8,856)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.33
(%)
2020, latest modelled
(0.28 - 0.39(%))
WHO
Prevalence PWID
HCV
64.33
(%)
2017, survey/surveillance
ECDC
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
No. of syringes/PWID/year
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines